Marker Therapeutics (MRKR) Change in Cash (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Change in Cash of -$1.4 million for Q1 2026, up 74.47% year-over-year from -$804852.9 in Q1 2025, and up 26.1% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) Change in Cash (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Change in Cash for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 74.47% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at $1.9 million (down 17.91% YoY), while the FY2025 annual figure was -$2.1 million, down 152.67% from the prior year.
- Change in Cash rose to -$1.4 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Change in Cash topped out at $11.7 million in Q2 2023 and bottomed at -$14.7 million in Q1 2022.
- Historically, Change in Cash has averaged -$1.6 million across 5 years, with a median of -$2.4 million in 2023.
- Annual changes were most pronounced in 2022 — Change in Cash sank 134.01% — and 2024, when it surged 531.45%.
- Marker Therapeutics' Change in Cash stood at -$6.3 million in 2022, then jumped by 62.47% to -$2.4 million in 2023, then soared by 531.45% to $10.2 million in 2024, then slumped by 118.64% to -$1.9 million in 2025, then gained by 26.1% to -$1.4 million in 2026.
- Business Quant data shows MRKR's Change in Cash at -$1.4 million in Q1 2026, -$1.9 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | -2.36 Mn |
| Sep 30, 2023 | -648,187.00 |
| Jun 30, 2023 | 11.72 Mn |
| Mar 31, 2023 | -5.38 Mn |
| Dec 31, 2022 | -6.29 Mn |
| Sep 30, 2022 | -7.75 Mn |
| Jun 30, 2022 | -3.00 Mn |
| Mar 31, 2022 | -14.68 Mn |
| Dec 31, 2021 | -5.21 Mn |
| Sep 30, 2021 | -8.52 Mn |
| Jun 30, 2021 | -7.29 Mn |